Topical imiquimod in combination with brachytherapy for unresectable cutaneous melanoma scalp metastases

JAAD Case Rep. 2022 Sep 17:31:62-65. doi: 10.1016/j.jdcr.2022.09.006. eCollection 2023 Jan.

Jennifer E Yeh^{1

2}, Marilyn T Wan^{1

3}, Allireza Alloo⁴, Nageatte Ibrahim^{5

6}, Ivan Buzurovic⁷, Jeffrey M Cohen^{1

8}, Patrick A Ott⁵, Alvaro C Laga⁵, Phillip M Devlin⁷, Jennifer Y Lin^{1

5}

¹ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Stanford University School of Medicine, Redwood City, California.
³ Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
⁴ Department of Dermatology, Northwell Health, Lake Success, New York.
⁵ Dana Farber Cancer Institute, Melanoma Program, Boston, Massachusetts.
⁶ Department of Oncology, Global Clinical Development, Merck & Co, Kenilworth, New Jersey.
⁷ Department of Radiation Oncology, Brigham & Women's/Dana Farber Cancer Institute Cancer Center, Boston, Massachusetts.
⁸ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.

No abstract available

Keywords: ITM, in-transit metastases; brachytherapy; imiquimod; immunomodulation; melanoma; radiation.

Publication types